Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 483

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab

Non-small cell lung cancer

Not recruiting

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoprotafib

Cardiac failure+1

Not recruiting

Preventing Heart Failure in Early Breast Cancer Patients Receiving Anthracycline Therapy with Sacubitril and Valsartan (LCZ696)

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sacubitril

Conjunctivitis allergic+1

Not recruiting

Dose‑finding trial of a mannan‑conjugated Phleum pratense/Dactylis glomerata allergoid vaccine in patients with grass‑pollen allergic rhinitis or rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bilastine

Breast cancer

Not recruiting

Study of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Skin wrinkling

Not recruiting

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Small cell lung cancer extensive stage

Not recruiting

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.